#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3881216	F	Antagonist activity at PGD2 receptor in human platelets assessed as inhibition of PGD2-mediated cAMP accumulation preincubated for 5 mins followed by PGD2 addition measured after 2 mins by HTRF assay	Homo sapiens	79		assay format	Patent Bioactivity Data
2.	ALA3881218	F	Agonist activity at human EP1 receptor expressed in HEK293 cells assessed as increase in intracellular calcium flux	Homo sapiens	79		cell-based format	Patent Bioactivity Data
3.	ALA3881219	F	Agonist activity at human EP1 receptor expressed in HEK293 cells assessed as increase in cAMP production	Homo sapiens	79		cell-based format	Patent Bioactivity Data
4.	ALA3881220	F	Agonist activity at human EP2 receptor expressed in HEK293 cells assessed as increase in intracellular calcium flux	Homo sapiens	79		cell-based format	Patent Bioactivity Data
5.	ALA3881221	F	Agonist activity at human EP2 receptor expressed in HEK293 cells assessed as increase in cAMP production	Homo sapiens	79		cell-based format	Patent Bioactivity Data
6.	ALA3881222	F	Agonist activity at human EP3 receptor expressed in HEK293 cells assessed as increase in intracellular calcium flux	Homo sapiens	79		cell-based format	Patent Bioactivity Data
7.	ALA3881223	F	Agonist activity at human EP3 receptor expressed in HEK293 cells assessed as increase in cAMP production	Homo sapiens	79		cell-based format	Patent Bioactivity Data
8.	ALA3881224	F	Agonist activity at human EP4 receptor expressed in HEK293 cells assessed as increase in intracellular calcium flux	Homo sapiens	79		cell-based format	Patent Bioactivity Data
9.	ALA3881225	F	Agonist activity at human EP4 receptor expressed in HEK293 cells assessed as increase in cAMP production	Homo sapiens	79		cell-based format	Patent Bioactivity Data
10.	ALA3881226	F	Agonist activity at human FP receptor expressed in HEK293 cells assessed as increase in intracellular calcium flux	Homo sapiens	79		cell-based format	Patent Bioactivity Data
11.	ALA3881227	F	Agonist activity at human FP receptor expressed in HEK293 cells assessed as increase in cAMP production	Homo sapiens	79		cell-based format	Patent Bioactivity Data
12.	ALA3881228	F	Agonist activity at human TP receptor expressed in HEK293 cells assessed as increase in intracellular calcium flux	Homo sapiens	79		cell-based format	Patent Bioactivity Data
13.	ALA3881229	F	Agonist activity at human TP receptor expressed in HEK293 cells assessed as increase in cAMP production	Homo sapiens	79		cell-based format	Patent Bioactivity Data
14.	ALA3881230	F	Agonist activity at human IP receptor expressed in HEK293 cells assessed as increase in intracellular calcium flux	Homo sapiens	79		cell-based format	Patent Bioactivity Data
15.	ALA3881231	F	Agonist activity at human IP receptor expressed in HEK293 cells assessed as increase in cAMP production	Homo sapiens	79		cell-based format	Patent Bioactivity Data
16.	ALA3881232	B	Selectivity ratio of IC50 for PGD2 receptor in human platelets to IC50 for human EP1 receptor expressed in HEK293 cells by cAMP accumulation assay	Homo sapiens	79		cell-based format	Patent Bioactivity Data
17.	ALA3881233	B	Selectivity ratio of IC50 for PGD2 receptor in human platelets to IC50 for human EP2 receptor expressed in HEK293 cells by cAMP accumulation assay	Homo sapiens	79		cell-based format	Patent Bioactivity Data
18.	ALA3881234	B	Selectivity ratio of IC50 for PGD2 receptor in human platelets to IC50 for human EP3 receptor expressed in HEK293 cells by cAMP accumulation assay	Homo sapiens	79		cell-based format	Patent Bioactivity Data
19.	ALA3881235	B	Selectivity ratio of IC50 for PGD2 receptor in human platelets to IC50 for human EP4 receptor expressed in HEK293 cells by cAMP accumulation assay	Homo sapiens	79		cell-based format	Patent Bioactivity Data
20.	ALA3881236	B	Selectivity ratio of IC50 for PGD2 receptor in human platelets to IC50 for human FP receptor expressed in HEK293 cells by cAMP accumulation assay	Homo sapiens	79		cell-based format	Patent Bioactivity Data